We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Ixico Plc | LSE:IXI | London | Ordinary Share | GB00BFXR4C20 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 8.75 | 8.50 | 9.00 | 8.75 | 8.75 | 8.75 | 0.00 | 07:33:41 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMIXI
RNS Number : 4442N
IXICO plc
08 August 2017
8 August 2017
IXICO plc
("IXICO" or the "Company")
Share option grant
IXICO plc (AIM: IXI) ('IXICO' or the 'Company'), the digital technologies company serving neuroscience, announces a grant of options over the ordinary shares in the Company in accordance with the rules of the Company's EMI Share Option Plan 2014 (the 'Plan') exercisable at a price of 34p (being the closing middle market price per ordinary share on 7 August 2017).
The award of options under the Plan is subject to certain performance conditions and the options granted will vest upon the achievement of strategic corporate goals in respect of commercialisation of the Company's products and/or services or a significant corporate development transaction occurring within three years of the date of grant.
The total number of options being issued at this time is 713,940 and includes a grant of options to Susan Lowther, Chief Financial Officer of the Company, as follows:
Hot Features
Premium
Name of Director Number of Total number Percentage
options of options held of issued share
granted capital under
option
------------------ ---------- ----------------- -----------------
Susan Lowther 235,000 545,196 2.01%
------------------ ---------- ----------------- -----------------
For further information please contact:
IXICO plc Giulio Cerroni, Chief Executive Tel: +44 20 3763 Officer 7499 Susan Lowther, Chief Financial Officer and Company Secretary Shore Capital (Nomad and Broker) Tel: +44 20 7408 Bidhi Bhoma / Edward Mansfield /James 4090 Wolfe FTI Consulting Limited (Investor Tel: +44 20 3727 Relations) 1000 Simon Conway/Mo Noonan
About IXICO
IXICO is the digital technologies company serving neuroscience. Our mission is to transform the pursuit of improving brain health through the application of digital technologies to neuroscience. IXICO's specialist data analytics services are used by the global pharmaceutical industry to select participants for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance. Our neurological disease focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, Parkinson's disease and our integrated digital platform encompasses the entire drug development lifecycle. It is a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable sponsors to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new companion digital health products targeted at improving patient outcomes.
More information is available on www.IXICO.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHEVLFBDVFLBBL
(END) Dow Jones Newswires
August 08, 2017 11:23 ET (15:23 GMT)
1 Year Ixico Chart |
1 Month Ixico Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
